Roche H1 2026: Diagnostics up 3% at CER as China drag persists
Roche's Diagnostics division posted CHF 6.7 billion in H1 2026, up 3% at constant exchange rates and 6% excluding China, where healthcare pricing reform continues to weigh on the segment.